# To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.

> **NCT01652209** · PHASE3 · COMPLETED · sponsor: **Pharmicell Co., Ltd.** · enrollment: 90 (actual)

## Conditions studied

- Acute Myocardial Infarction

## Interventions

- **BIOLOGICAL:** Hearticellgram-AMI

## Key facts

- **NCT ID:** NCT01652209
- **Lead sponsor:** Pharmicell Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-01
- **Primary completion:** 2024-08-12
- **Final completion:** 2024-08-12
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01652209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01652209, "To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01652209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*